Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 11 Dec 2024
- Closes
- 19 Oct 2026, 23:59 UTC
- Value
- USD 50,000
- Reference
- PAR-25-155
- Location
- United States
- Sector
- Healthcare & Pharma
Details
The purpose of this NOFO is to enhance the capability of NCATS CTSA Program KL2 scholars and recipients of re-entry supplements supported by the CTSA Program to conduct research as they complete the transition to fully independent academic translational scientists. These R03 grants will support different clinical and translational science research projects, including pilot and feasibility studies; secondary data analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support submission of a subsequent R01, or equivalent, application. Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
CFDA number(s): 93.350
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 399 open Healthcare & Pharma tenders in United States. This one closes in 25 days.
More from this buyer
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)· closes 10 Nov
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)· closes 17 Apr
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)· closes 10 Nov
- Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)· closes 25 May
Similar Healthcare & Pharma tenders
- Breathing Apparatus — Safety and Rescue Equipment· closes 26 Oct
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
- Development of innovative antimicrobials against pathogens resistant to antimicrobials· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- ФІЛІЯ «ЛОКОМОТИВНА КОМПАНІЯ» АКЦІОНЕРНОГО ТОВАРИСТВА «УКРАЇНСЬКА ЗАЛІЗНИЦЯ» invites bids for МилоФІЛІЯ «ЛОКОМОТИВНА КОМПАНІЯ» АКЦІОНЕРНОГО ТОВАРИСТВА «УКРАЇНСЬКА ЗАЛІЗНИЦЯ» · Ukraine
- Renovation of electrical services in Ward No 1 and main casualty area at Dr BSA Hospital Rohini DelhiPublic Works Department · CE/SE/B2-B24 · EE/B243(N) · India
- Repair work of road Patch by Hot Mix Plant From Chandan Medical Store to Transformer Ward63 Under Zone02Kanpur Municipal Corporation, Kanpur, UP · India
- Procurement of Cytotoxic Drugs used in Hormonal, Immuno, Supportive and ChemotherapyHEALTH · Mauritius
- Procurement of Cytotoxic Drugs Used in Targeted Therapy (Annual Requirements) Mhpq/Pharm/2026-2027/Q66 OIBHEALTH · Mauritius
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →